Modality
Bispecific Ab
MOA
KRASG12Di
Target
FXIa
Pathway
Fibrosis
CF
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
Mar 2021
→ Apr 2031
Phase 2Current
NCT06583518
80 pts·CF
2021-03→2031-04·Terminated
80 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-04-125.0y awayPh2 Data· CF
Trial Timeline
2021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2
Termina…
Catalysts
Ph2 Data
2031-04-12 · 5.0y away
CF
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06583518 | Phase 2 | CF | Terminated | 80 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Rimaosocimab | Amgen | Preclinical | FXIa |